Lucie Freiman

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 9

Top Venues

Leukemia

This page only lists publications with an associated author ORCID identifier.

Publications

Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Matthieu Duchmann, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Nicolas Duployez, Emmanuelle Clappier, Marie Sébert
Germline CHEK2 mutations in patients with myeloid neoplasms. Leukemia 38 (4) (2024)
Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Matthieu Duchmann, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Nicolas Duployez, Emmanuelle Clappier, Marie Sébert
Germline CHEK2 mutations in patients with myeloid neoplasms. Leukemia (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia 38 (4) (2024)
Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Matthieu Duchmann, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Nicolas Duployez, Emmanuelle Clappier, Marie Sébert
Germline CHEK2 mutations in patients with myeloid neoplasms. Leukemia 38 (4) (2024)
Marie Sébert, Lucie Freiman, Cendrine Chaffaut, Agnès Guerci, Pierre Peterlin, Sylvain Thépot, Odile Beyne-Rauzy, Sophie Park, Thomas Cluzeau, Fatiha Chermat, Pierre Fenaux, Claude Preudhomme, Emmanuelle Clappier, Sylvie Chevret, Lionel Ades, Nicolas Duployez, Matthieu Duchmann
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens. Leukemia (2024)
Lucie Freiman, Lise Larcher, Giulia Tueur, Nadia Vasquez, Mélanie Da Costa, Matthieu Duchmann, Emmanuel Raffoux, Lionel Ades, Pierre Fenaux, Jean Soulier, Nicolas Duployez, Emmanuelle Clappier, Marie Sébert
Germline CHEK2 mutations in patients with myeloid neoplasms. Leukemia 38 (4) (2024)

Lucie Freiman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lucie Freiman